Centrus Energy Corp. is a trusted supplier of nuclear fuel components for the nuclear power industry, providing enrichment and technical services for public and private customers. The company operates through a global network of suppliers to deliver low-enriched uranium (LEU) and related products that are essential for electricity generation in nuclear reactors.
The company generates revenue primarily from the sale of LEU, which includes the separative work unit (SWU)…
Centrus Energy Corp. is a trusted supplier of nuclear fuel components for the nuclear power industry, providing enrichment and technical services for public and private customers. The company operates through a global network of suppliers to deliver low-enriched uranium (LEU) and related products that are essential for electricity generation in nuclear reactors.
The company generates revenue primarily from the sale of LEU, which includes the separative work unit (SWU) component and natural uranium hexafluoride, to utilities that operate commercial nuclear power plants. In addition, Centrus earns revenue from its Technical Solutions segment by providing advanced uranium enrichment, manufacturing, and other technical services to government and private sector customers. These revenue streams are supported by long-term contracts with utilities and government agencies such as the U. S. Department of Energy.
The company operates through the following segments: LEU and Technical Solutions.
• LEU: This segment supplies various components of nuclear fuel to commercial customers from our global network of suppliers.
• Technical Solutions: This segment provides advanced uranium enrichment for the nuclear industry and the U. S. government and advanced manufacturing and other technical services to government and private sector customers.
Centrus holds a niche position in the global uranium enrichment market, accounting for less than 5% of the approximately 50 million SWU per year demand for low-enriched uranium. Its primary competitors are state-owned entities such as Rosatom/TENEX, Urenco, CNEIC, and Orano, which together control over 95% of the market. A key competitive advantage is the company’s deployment of the AC100M centrifuge, the only U. S.-origin enrichment technology capable of producing high-assay low-enriched uranium (HALEU) up to 20% U-235, which meets national security requirements. Additionally, Centrus leverages its long-term supply contracts, diverse sourcing, and growing backlog to provide reliable and flexible supply to customers.
The company’s customer base consists mainly of domestic and international utilities that operate nuclear power plants worldwide. It also serves the U. S. Department of Energy and other government agencies through its Technical Solutions segment.
Sectors:Energy · IndustrialsSector rationaleThe company's primary revenue comes from the sale of low-enriched uranium (LEU) and separative work units (SWU) to nuclear utilities, which falls under the Energy sector's scope for uranium conversion and fuel fabrication. A secondary sector of Industrials is justified because the Technical Solutions segment provides advanced manufacturing and other technical services to government and private sector customers.Industries:UraniumEnergyPrimaryCentrus Energy's primary business is the supply of nuclear fuel components, specifically low-enriched uranium (LEU) and high-assay low-enriched uranium (HALEU). The company generates revenue from the sale of separative work units (SWU) and natural uranium hexafluoride to nuclear power plant utilities.Nuclear EquipmentIndustrialsSecondaryThrough its Technical Solutions segment, the company provides advanced manufacturing and technical services to government and private sector customers. This includes the deployment of the AC100M centrifuge technology for uranium enrichment.Classified using BQ-MICSCIK: 0001065059
Investment Thesis
▲ Bull case
Centrus Energy's strategic partnerships and operational advancements are positioning it to capture outsized value from the global nuclear renaissance, particularly through its HALEU capabilities which are becoming indispensable for advanced reactor deployment. The company's recent $900 million DOE HALEU enrichment award, with potential to exceed $1 billion, provides a near-term revenue catalyst that management did not fully emphasize during the call, as they framed it as pending finalization despite its near-certainty given the strategic importance of domestic HALEU supply. This contract alone could deliver meaningful HALEU-based revenue starting in late 2026, supplementing the already robust $3.9 billion commercial backlog, of which $2.4 billion is under definitive LEU agreement. Crucially, the HALEU award mitigates volume risk by guaranteeing a baseline of demand while allowing Centrus to leverage its pricing power in an increasingly tight supply environment, where SWU prices rose 52% year-over-year despite a 47% volume decline, demonstrating strong pricing elasticity. The market is underestimating how quickly this pricing strength will translate into margin expansion as fixed costs are spread over higher-value output, especially given the company's identification of $300 million in cost savings through the Palantir partnership—a figure that represents nearly 80% of its current quarterly revenue and signals transformative operational efficiency gains not yet reflected in earnings. Furthermore, the exploration of a deconversion JV with Oklo addresses a critical commercial gap in the HALEU fuel cycle, potentially enabling vertical integration that could capture additional margin and lock in long-term offtake from advanced reactor developers who require both enrichment and deconversion services. With unrestricted cash of $1.9 billion and no reliance on the ATM program, Centrus has a fortress balance sheet to fund its $350–$500 million capex plan without dilution, while workforce acceleration in Piketon and Oak Ridge—now targeting over 100 net new hires each—suggests build-out progress is ahead of schedule, reducing execution risk and accelerating the path to nth-of-a-kind cost advantages. The convergence of government backing, technological differentiation via American-owned centrifuge IP, and surging demand from both utilities and hyperscalers creates a structural tailwind that could drive sustained revenue growth well beyond the raised 2026 guidance of $450–$500 million, positioning Centrus as a indispensable domestic supplier in a market where foreign enrichment capacity faces geopolitical and regulatory headwinds.
Centrus Energy's strategic partnerships and operational advancements are positioning it to capture outsized value from the global nuclear renaissance, particularly through its HALEU capabilities which are becoming indispensable for advanced reactor deployment. The company's recent $900 million DOE HALEU enrichment award, with potential to exceed $1 billion, provides a near-term revenue catalyst that management did not fully emphasize during the call, as they framed it as pending finalization despite its near-certainty given the strategic importance of domestic HALEU supply. This contract alone could deliver meaningful HALEU-based revenue starting in late 2026, supplementing the already robust $3.9 billion commercial backlog, of which $2.4 billion is under definitive LEU agreement. Crucially, the HALEU award mitigates volume risk by guaranteeing a baseline of demand while allowing Centrus to leverage its pricing power in an increasingly tight supply environment, where SWU prices rose 52% year-over-year despite a 47% volume decline, demonstrating strong pricing elasticity. The market is underestimating how quickly this pricing strength will translate into margin expansion as fixed costs are spread over higher-value output, especially given the company's identification of $300 million in cost savings through the Palantir partnership—a figure that represents nearly 80% of its current quarterly revenue and signals transformative operational efficiency gains not yet reflected in earnings. Furthermore, the exploration of a deconversion JV with Oklo addresses a critical commercial gap in the HALEU fuel cycle, potentially enabling vertical integration that could capture additional margin and lock in long-term offtake from advanced reactor developers who require both enrichment and deconversion services. With unrestricted cash of $1.9 billion and no reliance on the ATM program, Centrus has a fortress balance sheet to fund its $350–$500 million capex plan without dilution, while workforce acceleration in Piketon and Oak Ridge—now targeting over 100 net new hires each—suggests build-out progress is ahead of schedule, reducing execution risk and accelerating the path to nth-of-a-kind cost advantages. The convergence of government backing, technological differentiation via American-owned centrifuge IP, and surging demand from both utilities and hyperscalers creates a structural tailwind that could drive sustained revenue growth well beyond the raised 2026 guidance of $450–$500 million, positioning Centrus as a indispensable domestic supplier in a market where foreign enrichment capacity faces geopolitical and regulatory headwinds.
Centrus Energy's apparent operational progress masks significant execution risks and financial headwinds that the market is overlooking, particularly regarding the convertibility of its massive backlog into near-term cash flow and the sustainability of its recent pricing gains. Despite a $3.9 billion commercial backlog, only $2.4 billion of LEU backlog is under definitive agreement, with the remaining $700 million classified as broker-dealer backlog—typically less binding and subject to cancellation or renegotiation—raising concerns about the quality and reliability of the stated pipeline. Furthermore, the LEU segment revenue declined 13% year-over-year due to a 47% drop in SWU volume, which was only partially offset by a 52% increase in average SWU price; this volatile mix shift suggests that revenue growth is increasingly dependent on pricing power rather than volume expansion, a precarious position if global uranium supply improves or demand from existing reactors softens due to economic headwinds or extended outages. The company's reliance on opportunistic uranium sales—explicitly noted by CFO Todd Tinelli as unpredictable and quarterly-concentrated—further undermines revenue predictability, especially given that gross profit declined year-over-year to $31.5 million from $32.9 million despite higher SWU prices, indicating that cost pressures are eroding margins even in a favorable pricing environment. Management's emphasis on adjusted metrics—such as adjusted net income of $23.5 million versus reported $10 million—reveals that core profitability is being inflated by excluding $17 million in growth expenses and Palantir-related prepayments, which are very real, recurring costs associated with the build-out and should not be dismissed as one-time if the expansion continues over multiple years. While the $300 million in identified cost savings from the Palantir partnership sounds impressive, it remains largely aspirational and unverified, with no clear timeline for realization, and the $5 million prepayment for Palantir services already represents a drag on current earnings without proven offsetting benefits. The Oak Ridge centrifuge manufacturing expansion, backed by a $560 million investment, carries significant technology and schedule risk, as scaling first-of-a-kind centrifuge production has historically faced delays and cost overruns, and Centrus has not provided granular milestones or third-party validation for its progress claims. Additionally, the exploration of a deconversion JV with Oklo, while strategically sensible, highlights a critical gap in Centrus's current capabilities—deconversion does not exist commercially—and entering this space via partnership could dilute returns and increase complexity without guaranteed commercial viability, especially if Oklo's own timelines slip. Finally, the company's heightened workforce targets—over 100 net new hires at both Piketon and Oak Ridge—suggest accelerating labor costs at a time when operating income was a mere $0.8 million in the quarter, raising concerns that the burn rate is outpacing tangible progress, particularly given that only one-third of critical partner contracts have been finalized despite reaffirmed 2026 completion guidance, implying potential delays in the build-out timeline that could push revenue recognition further into the future and strain the cash balance despite its current size.
Centrus Energy's apparent operational progress masks significant execution risks and financial headwinds that the market is overlooking, particularly regarding the convertibility of its massive backlog into near-term cash flow and the sustainability of its recent pricing gains. Despite a $3.9 billion commercial backlog, only $2.4 billion of LEU backlog is under definitive agreement, with the remaining $700 million classified as broker-dealer backlog—typically less binding and subject to cancellation or renegotiation—raising concerns about the quality and reliability of the stated pipeline. Furthermore, the LEU segment revenue declined 13% year-over-year due to a 47% drop in SWU volume, which was only partially offset by a 52% increase in average SWU price; this volatile mix shift suggests that revenue growth is increasingly dependent on pricing power rather than volume expansion, a precarious position if global uranium supply improves or demand from existing reactors softens due to economic headwinds or extended outages. The company's reliance on opportunistic uranium sales—explicitly noted by CFO Todd Tinelli as unpredictable and quarterly-concentrated—further undermines revenue predictability, especially given that gross profit declined year-over-year to $31.5 million from $32.9 million despite higher SWU prices, indicating that cost pressures are eroding margins even in a favorable pricing environment. Management's emphasis on adjusted metrics—such as adjusted net income of $23.5 million versus reported $10 million—reveals that core profitability is being inflated by excluding $17 million in growth expenses and Palantir-related prepayments, which are very real, recurring costs associated with the build-out and should not be dismissed as one-time if the expansion continues over multiple years. While the $300 million in identified cost savings from the Palantir partnership sounds impressive, it remains largely aspirational and unverified, with no clear timeline for realization, and the $5 million prepayment for Palantir services already represents a drag on current earnings without proven offsetting benefits. The Oak Ridge centrifuge manufacturing expansion, backed by a $560 million investment, carries significant technology and schedule risk, as scaling first-of-a-kind centrifuge production has historically faced delays and cost overruns, and Centrus has not provided granular milestones or third-party validation for its progress claims. Additionally, the exploration of a deconversion JV with Oklo, while strategically sensible, highlights a critical gap in Centrus's current capabilities—deconversion does not exist commercially—and entering this space via partnership could dilute returns and increase complexity without guaranteed commercial viability, especially if Oklo's own timelines slip. Finally, the company's heightened workforce targets—over 100 net new hires at both Piketon and Oak Ridge—suggest accelerating labor costs at a time when operating income was a mere $0.8 million in the quarter, raising concerns that the burn rate is outpacing tangible progress, particularly given that only one-third of critical partner contracts have been finalized despite reaffirmed 2026 completion guidance, implying potential delays in the build-out timeline that could push revenue recognition further into the future and strain the cash balance despite its current size.